Literature DB >> 7582495

Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells.

H Azuma1, J Sato, H Hamasaki, A Sugimoto, E Isotani, S Obayashi.   

Abstract

1. We examined regeneration of endothelial cells (ECs), neointima formation, decreased endothelium-dependent relaxation (EDR) and changes in the contents of L-arginine, NG-monomethyl-L-arginine (L-NMMA), asymmetrical NG, NG-dimethylarginine (ADMA) and symmetrical NG,NG-dimethylarginine (SDMA) in the regenerated ECs, 6 weeks after balloon denudation of the rabbit carotid artery. 2. Regeneration of ECs was completed in 6 weeks and a significant neointima formation accompanied by the decreased EDR was observed. 3. L-NMMA and ADMA contents in the regenerated ECs (23.5 +/- 4.3 and 21.2 +/- 2.0 pmol mg-1 DNA, respectively) were significantly (P < 0.05 and P < 0.01) higher than those in the control ECs (8.8 +/- 3.0 and 7.4 +/- 1.9 pmol mg-1 DNA, respectively), whereas L-arginine was significantly (P < 0.005) decreased in the regenerated ECs (31,470 +/- 1,050 pmol mg-1 DNA) as compared to that in the control ECs (47,870 +/- 1,890 pmol mg-1 DNA). SDMA content was below the assay limits. 4. L-NMMA and ADMA, but not SDMA, inhibited the EDR induced by acetylcholine in a concentration-dependent manner. The inhibition with L-NMMA and ADMA was prevented by an addition of L-arginine, but not by D-arginine. 5. These results suggest that the accumulation of endogenous inhibitors for nitric oxide synthesis and decreased L-arginine content are associated with decreased NO production/release from regenerated ECs and neointima formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582495      PMCID: PMC1909001          DOI: 10.1111/j.1476-5381.1995.tb15910.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system.

Authors:  J M KISSANE; E ROBINS
Journal:  J Biol Chem       Date:  1958-07       Impact factor: 5.157

2.  Regeneration of endothelial cells after balloon denudation of the rabbit carotid artery and changes in responsiveness.

Authors:  H Azuma; N Funayama; T Kubota; M Ishikawa
Journal:  Jpn J Pharmacol       Date:  1990-04

3.  Repeated endothelial removal augments intimal thickening and attenuates EDRF release.

Authors:  Y Niimi; H Azuma; K Hirakawa
Journal:  Am J Physiol       Date:  1994-04

4.  Endothelin is a potent mitogen for rat vascular smooth muscle cells.

Authors:  Y Hirata; Y Takagi; Y Fukuda; F Marumo
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

5.  The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

6.  Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.

Authors:  C Boulanger; T F Lüscher
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

Review 7.  Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.

Authors:  J H Ip; V Fuster; L Badimon; J Badimon; M B Taubman; J H Chesebro
Journal:  J Am Coll Cardiol       Date:  1990-06       Impact factor: 24.094

8.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.

Authors:  P Vallance; A Leone; A Calver; J Collier; S Moncada
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

9.  Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan.

Authors:  H Azuma; Y Niimi; H Hamasaki
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

10.  Role of endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries.

Authors:  H Azuma; H Hamasaki; Y Niimi; T Terada; O Matsubara
Journal:  Am J Physiol       Date:  1994-12
View more
  12 in total

1.  Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia.

Authors:  H Masuda; T Tsujii; T Okuno; K Kihara; M Goto; H Azuma
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.

Authors:  Hasan Ari; Selma Ari; Ercan Erdoğan; Osman Tiryakioğlu; Yasemin Ustündağ; Kağan Huysal; Vedat Koca; Tahsin Bozat
Journal:  Heart Vessels       Date:  2010-01-21       Impact factor: 2.037

Review 3.  [Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor].

Authors:  Friedrich Mittermayer; Katarzyna Krzyzanowska; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 4.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

5.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.

Authors:  J M Leiper; J Santa Maria; A Chubb; R J MacAllister; I G Charles; G S Whitley; P Vallance
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

6.  Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia.

Authors:  H Masuda; M Goto; S Tamaoki; H Azuma
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  Transient endothelial dysfunction following flow-mediated dilation assessment.

Authors:  Roberto Nerla; Antonio Di Monaco; Alfonso Sestito; Priscilla Lamendola; Enrico Di Stasio; Federica Romitelli; Gaetano Antonio Lanza; Filippo Crea
Journal:  Heart Vessels       Date:  2010-12-09       Impact factor: 2.037

8.  Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.

Authors:  P Cetinalp-Demircan; A Can; Selda Bekpinar; Y Unlucerci; Y Orhan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

9.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05

10.  Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease.

Authors:  Tse-Min Lu; Yu-An Ding; Min-Ji Charng; Shing-Jong Lin
Journal:  Clin Cardiol       Date:  2003-10       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.